- $23.34bn
- $27.11bn
- $3.72bn
European shares rise as retreating bond yields and oil prices boost risk appetite
Live Markets: Oil prices can rise even with a new MoU
Live Markets: What the AI capex cycle might mean for European growth
Live Markets: Ignore politics and buy the dip in Spain's Bonos
European shares gain as Genmab jumps, bond yields retreat
Live Markets: A health boost for the STOXX
Genmab at 3-year high after blood cancer drug combination study results
European shares gain as Genmab jumps, bond yields retreat
Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study (updated)
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Genmab jumps as ovarian cancer data bolster confidence ahead of Phase III readout
Europe Research Roundup: Amplifon, Continental, Tecan Group
Canada Research Roundup: Canadian National Railway, Intact Financial, Wellstar Technologies
Brief: Genmab Says Treatment With Rina-S Demonstrated Clinically Meaningful Objective Response Rate
Live Markets: Latest yen intervention format burnishes dollar's status, say Goldman
Live Markets: Europe Inc powers past lofty Q2 profit expectations
Live Markets: STOXX heads for decent weekly rise
Genmab jumps on Q2 beat, guidance hike
Genmab A/S reports results for the quarter ended June 30 - Earnings Summary